Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
October 26, 2026

Pathos AI completes $237m Series E round to expand oncology pipeline

Pathos AI has secured $237m in a Series E financing round to expand its clinical oncology pipeline and scale its AI drug development platform.

Continue
Pathos AI uses the platform to identify patient sub-populations, redirect clinical trial strategies, and remove high-risk drug projects. Credit: Gorodenkoff / Shutterstock.com.
October 26, 2026

Lunit and Summit to evaluate pathology platform for tumour analysis

The companies plan to utilise Lunit SCOPE IO to identify biomarkers, stratify patients, and investigate biological responses to ivonescimab. Credit: Gorodenkoff / Shutterstock.com.
October 23, 2026

Boehringer and Microsoft collaborate to explore AI in clinical research

The initiative links with Boehringer Ingelheim’s adoption of Microsoft Copilot across its human pharmaceutical operations. Credit: Michael Vi / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Celltrion and Kaigene sign $580m licence deal for KG013
  2. Astellas and AI Proteins sign miniprotein therapeutics deal
  3. MSD’s Keytruda and Padcev combination receives EC approval
  4. FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease
  5. Sanofi and ScionxBio partner on mRNA therapies

PRESS RELEASES

Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Gerresheimer Reports Slight Revenue Growth in Q1 2026 and a Strong Focus on Free Cash Flow
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
Uwe Röhrhoff Steps Down as Interim CEO of Gerresheimer AG
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
SCHOTT Pharma Expands Portfolio for Sensitive Biologics with cartriQ® BioPure
Pharmaceutical Business Review
SCHOTT Pharma and Nemera Deliver Verified Pen Injector Platform with Sterile Cartridge System
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary
SCHOTT Pharma Invests in Sterile Cartridge Production in Hungary

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography